POSTER SESSION: New Therapies in Immuno-Oncology| Volume 138, SUPPLEMENT 2, S58, October 2020

TAS1553, a novel class of RNR inhibitor, has robust antitumor activity in murine syngeneic tumor models as a single agent and in combination with anti-PD-1 checkpoint inhibitor

      Background: Deoxyribonucleoside triphosphates (dNTPs) are the building blocks of DNA and are essential for cancer cell growth and survival. Ribonucleotide reductase (RNR) regulates a rate-limiting step in the supply of dNTP, which suggests RNR as a promising therapeutic target of cancer. TAS1553 is a novel class of RNR inhibitor that abrogates protein-protein interactions between RNR subunits; this compound has shown promising antitumor activity in preclinical models for both solid tumors and hematological malignancies.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect